MS

Increased Anesthesia Volume May Provide Longer Pain Relief During Dental Procedures

Retrieved on: 
Wednesday, October 25, 2023
Female, Patient, Incidence, Adrenaline, Maxillary, Private practice, Male, Dentist, DMD, Anxiety, Pain, Maxilla, MS, Dentistry, Pharmaceutical industry, Anesthesia

LAWRENCE, Kan. , Oct. 25, 2023 /PRNewswire-PRWeb/ -- Anesthesia Progress – A typical cause of anxiety around dental visits is a fear of pain during a procedure. While many techniques and strategies exist to control the pain, some patients still report feeling a certain amount of pain, especially during more lengthy or complex procedures. One of the most common methods that dentists employ for pain control is using anesthesia to help numb the treatment area; however, anesthesia's effectiveness can wear off before the procedure is complete, leaving the patient with no recourse for the pain until the procedure is over.

Key Points: 
  • LAWRENCE, Kan. , Oct. 25, 2023 /PRNewswire-PRWeb/ -- Anesthesia Progress – A typical cause of anxiety around dental visits is a fear of pain during a procedure.
  • This study shows that increasing the volume of anesthesia from 1.8 to 3.4 mL for lengthy dental procedures provided a longer pain control duration in procedures lasting more than 48 minutes.
  • However, it also highlighted the need for additional action in administering additional anesthesia for longer dental procedures to ensure optimal patient comfort.
  • Woo and colleagues state that anesthesia "reinjection could be a clinical strategy to ensure adequate anesthesia in the maxilla for procedures lasting 60 minutes or longer."

Family Physicians with Value-Based Payment Models Relieve Burnout, According to Study from AAFP on Elation Health

Retrieved on: 
Wednesday, October 25, 2023
Burnout, AAFP, Physician, Health, Organization, Research, Harvard Innovation Labs, Interview, Elation, American Academy, Risk, American Academy of Family Physicians, FMX, Movement, Patient, MS, SAN, VBP, Pharmaceutical industry, Nursing, MD

SAN FRANCISCO, Oct. 25, 2023 /PRNewswire/ -- Elation Health, the clinical-first technology company powering innovation in primary care, announced today that the American Academy of Family Physicians (AAFP) Innovation Lab, which identifies key innovations that optimize the family medicine experience, has issued the results of a second collaborative study. The goal of the study this year, conducted by surveying 10 primary care practices of varying sizes, was to identify specific barriers and innovations required for mainstream adoption of value-based payment (VBP) models and their relationship to physician burnout.

Key Points: 
  • "In this second study with Elation Health, we found it critical to further explore the challenges family physicians face as they work to transition to value-based payment models and to understand which innovations help them break through these barriers without putting themselves at risk of burnout."
  • According to another recent AAFP study, more than half of family physicians report being burned out.
  • Key findings from the study illustrate both the promise and the challenges involved with VBP models.
  • Capitation Factors: Practices with capitated models, or risk-adjusted, per-person payment models, experienced less burnout than those with payment models designed around retrospective "bonus" payments.

Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics

Retrieved on: 
Tuesday, October 24, 2023
Sequence, WES, MPH, Biomarker, Therapy, Doctor of Philosophy, MBA, Data science, MRNA, Disease, Medicine, Messenger, Probability, AI, Patient, MS, Pharmaceutical industry, Medical imaging, MD, Moderna

IRVING, Texas, Oct. 24, 2023 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced a new agreement with Moderna (NASDAQ:MRNA) in support of Moderna's oncology and novel therapeutics initiatives.

Key Points: 
  • "Partnering with Caris Life Sciences will support Moderna's oncology portfolio with clinico-genomics data from Caris' industry-leading and comprehensive suite of integrated precision medicine capabilities," stated Praveen Aanur, MD, MPH, MBA, Vice President, Oncology Therapeutic Area Head of Moderna.
  • "We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives," said David Spetzler , MS, PhD, MBA, President of Caris Life Sciences.
  • As the pioneer in precision medicine and molecular profiling, Caris has created the largest clinico-genomic database coupled with cognitive computing to unravel the molecular complexity of disease.
  • Caris was the first in the industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES / WTS) for every patient.

COVID Disruptions to Cost Multiple Sclerosis Community $600-Million

Retrieved on: 
Wednesday, October 18, 2023
Epstein–Barr virus, Health, Mortality, Research, HIV disease progression rates, Economics, Research report, Quality of life, Disease, COVID, COVID-19, Risk, Disability, EBV, Nursing, Diagnosis, MS, Central nervous system, Pharmaceutical industry

OTTAWA, Oct. 18, 2023 (GLOBE NEWSWIRE) -- A new research report by Deloitte Access Economics concluded that emergency COVID-19 health measures have had a severe negative impact on Canada’s multiple sclerosis (MS) community.

Key Points: 
  • OTTAWA, Oct. 18, 2023 (GLOBE NEWSWIRE) -- A new research report by Deloitte Access Economics concluded that emergency COVID-19 health measures have had a severe negative impact on Canada’s multiple sclerosis (MS) community.
  • This COVID “gap” is expected to get worse, unless immediate steps are taken to remedy the delayed diagnosis and foregone treatment.
  • The COVID-19 disruption caused worse outcomes for Canadians living with MS through delayed MS diagnosis, and delayed or foregone MS treatment.
  • Canada must do the same, as this is ‘Canada’s disease’.” – Dr. Pamela Valentine, President and CEO of MS Canada

Children’s Hospital Los Angeles Researchers Develop Clinical Tool to Predict if a Child in Acute Liver Failure Will Need a Transplant

Retrieved on: 
Monday, October 23, 2023
Software, Research, Internet, Family, Consumer, Apps, Applications, Technology, Hospitals, Children, Science, Surgery, Health, Liver injury, Child, Children's Hospital Los Angeles, PELD, Smartphone, Liver, MD, USC, Viral hepatitis, Cirrhosis, Doctor of Philosophy, FRCSC, MBBS, Immune-mediated inflammatory diseases, FACS, King's College Hospital NHS Foundation Trust, Division, Chronic liver disease, Risk, National Cancer Institute, CHLA, Nutrition, Probability, King's College Hospital, Hepatotoxicity, Liver failure, NIH, MHA, Hospital, Patient, Transplant, Acute liver failure, Diagnosis, Death, MS, Dietary supplement, Birth control, Gastroenterology

Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.

Key Points: 
  • Unlike children with chronic liver disease, previously healthy children who develop acute liver failure can suddenly deteriorate.
  • While pediatric acute liver failure has been linked to both viral hepatitis and drug-induced liver injury, at least half of cases have no apparent trigger.
  • The CHALF Score predicts if a child experiencing acute liver failure will recover or should be referred to a transplant center.
  • Doctors do not want to refer a child for liver transplant who could otherwise recover with medical treatment—about 70% of children with acute liver failure recover while keeping their original liver.

Iterative Health Presents Award-Winning Research on the Benefits of Gastroenterological Technology at the American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
Monday, October 23, 2023
Technology, Surgery, Medical Devices, Medical Supplies, Clinical Trials, Other Health, Health, General Health, Artificial Intelligence, GI, FDA, Intelligence, American College, Harvard Medical School, Crohn's disease, MPH, Outline of health sciences, Adenoma, Use, ACG, Prevalence, Rutgers University–New Brunswick, Cade, Publication, Doctor of Philosophy, MBA, American College of Gastroenterology, Research, Computer science, Computer-aided, George Washington University School of Medicine & Health Sciences, Artificial intelligence, APC, Colonoscopy, School, University of North Dakota, CRC, Clinical trial, Abstract, University, Medical diagnosis, Mount Auburn Hospital, Safety, Boston Medical Center, Inflammatory bowel disease, MS, Medical imaging, Management, Medical device, Gastroenterology, MD, Colitis, Geriatrics, Medicine

Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, announced today the results of new research unveiled at the American College of Gastroenterology (ACG) Annual Scientific Meeting.

Key Points: 
  • Iterative Health , a pioneer in precision-medicine technologies for gastroenterology, announced today the results of new research unveiled at the American College of Gastroenterology (ACG) Annual Scientific Meeting.
  • This research represents strides toward enhancing the detection of precursor adenomas and streamlining clinical trial recruitment processes in gastroenterology, ultimately bringing us closer to a future of advancing patient care in the field.
  • The publications include:
    Authors: William Holderman, MD; Parth Jain; Mitchell Reddan, MS; Haig Soghigian, MBA; Christopher Fourment, MD.
  • To learn more about Iterative Health, please visit iterative.health .

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

Retrieved on: 
Saturday, October 21, 2023
Oncology, Health, Biometrics, Health Technology, Clinical Trials, Biotechnology, Patient, Francis Crick Institute, NSCLC, University College London, ESMO, Lung cancer, Congress, PPM, Publication, Professor, Adenocarcinoma, Fear, R, UCL, Death, LUAD, Risk, Recurrence, MRD, Risk assessment, CT, Blood, PSNL, European Society for Medical Oncology, NeXT, Cancer, Neoplasm, MS, DNA, Medical imaging, MD, Chief Justice of Hungary

(Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management.

Key Points: 
  • (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management.
  • Lung cancer is the second most common cancer in the U.S., with an estimated 238,000 new cases and approximately 127,000 deaths forecasted for 2023.
  • For the current analysis, the teams used NeXT Personal to identify and track MRD in over 170 patients from the TRACERx cohort.
  • The study demonstrated that pre-surgical ctDNA levels with NeXT Personal could be used to classify early-stage lung cancer patients into lower- and higher-recurrence risk groups.

Vagus nerve stimulation reduces inflammation in children with Inflammatory Bowel Disease, Feinstein Institutes study finds

Retrieved on: 
Wednesday, October 18, 2023
Research, Managed Care, General Health, Consumer, Medical Devices, Children, Science, Biotechnology, Neurology, Practice Management, Other Science, Health, Abdominal pain, Child, MRI, Medical research, Feinstein, Inflammation, Feinstein Institutes for Medical Research, Cohen, FC, Vagus nerve, Weatherall Institute of Molecular Medicine, Heart rate, Diarrhea, Human, Medicine, Prevalence, Vagus nerve stimulation, Incontinence, Diabetes, Rheumatoid arthritis, MBA, Electricity, TENS, Bleeding, GE Research, Ulcerative colitis, Multimedia, Northwell Health, Disease, Clinical trial, Nature Communications, Pulmonary hypertension, Neuroscience, Ear, Arthritis, IBD, Sickle Cell Anemia, a Molecular Disease, Credit, Molecular medicine, Brain, Cancer, Patient, Liver disease, Biomedical engineering, Bangladesh Technical Education Board, MS, Central nervous system, Lupus, Medical imaging, Pharmaceutical industry, Management, Gastroenterology, MD

View the full release here: https://www.businesswire.com/news/home/20231018401966/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231018401966/en/
    The Feinstein Institutes for Medical Research’s Dr. Benjamin Sahn led the vagus nerve stimulation clinical trial.
  • Inflammation and the inflammatory reflex – the neuronal signaling between the brain and body – is an important immune response.
  • Previous research and functional MRI studies have mapped stimulation of the auricular branch of the vagus nerve to activate the same brain regions as implanted devices, confirming this nerve as a suitable non-invasive target to administer vagus nerve stimulation.
  • Also, Feinstein Institutes researchers, in collaboration with GE Research, published research that harnessed ultrasound technology to reduce inflammation in the body non-invasively.

Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.

Retrieved on: 
Wednesday, October 18, 2023
Research, Hospitals, Health Technology, Stem Cells, Biotechnology, Training, University, Health, Science, Education, Cellular senescence, Regenerative medicine, PD, Cell biology, Urethral stricture, IDC, Tissue engineering, FCQ, Sri Ramachandra Institute of Higher Education and Research, Cell, GSZ, Multimedia, Tree (graph theory), Code, Tissue, German Society for Stem Cell Research, Genome, Kasturba Medical College, Disease, Buccal, University of Cologne, Duchenne muscular dystrophy, XVIII, Radboud University Medical Center, Hospital, Chondrocyte, McEwen Centre for Regenerative Medicine, Stem cell, Multiple sclerosis, NCRM, Thai-Nichi Institute of Technology, Safety, DMD, Autism spectrum, Synthetic biology, ASD, Edogawa, MS, B cell, Pharmaceutical industry, RM

This press release features multimedia.

Key Points: 
  • This press release features multimedia.
  • Winners and finalists of Fujio Cup Quiz (FCQ), the “FCQ Elites” are qualified to nominate the candidates for the Edogawa NICHE Prize.
  • The inaugural prize in 2018 was awarded to Prof. James E. Till for discovery of stem cells, jointly with Prof. Ernest McCulloch.
  • NCRM NICHE team is progressing in research on implications of microgravity, synthetic chemical concoctions, and biological response modifiers, on cellular senescence and immune modulation to develop solutions, especially for rare diseases and unmet needs.

Marissa Renardy, PhD, of Applied BioMath, Receives ISoP Emerging Scientist Award

Retrieved on: 
Friday, October 20, 2023
Harvard John A. Paulson School of Engineering and Applied Sciences, Mathematical and theoretical biology, OH, BS, MD, Doctor of Philosophy, Research, R, Statistics, COVID-19, Doctor of Pharmacy, Ohio State University, Utta Isop, University, Tuberculosis, Immunology, MS, Pharmaceutical industry, Microbiology, Mathematics, Virginia Tech

CONCORD, Mass., Oct. 20, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced Marissa Renardy, PhD, Principal Scientist at Applied BioMath received ISoP's Emerging Scientist Award.

Key Points: 
  • CONCORD, Mass., Oct. 20, 2023 /PRNewswire/ -- Applied BioMath ( www.appliedbiomath.com ), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced Marissa Renardy, PhD, Principal Scientist at Applied BioMath received ISoP's Emerging Scientist Award.
  • Dr. Renardy will be recognized at the ACoP14 opening session and ISoP award's ceremony on Sunday, November 5, 2023.
  • The ISoP Emerging Scientist Award recognizes early-career scientists who are within five years of earning their MS, PharmD, PhD, or MD degree, and have made extraordinary impact in the fields of pharmacometrics, applied statistics, systems-based modeling and simulation, or a related scientific area.
  • "This is a very well-deserved recognition for Dr. Renardy," said John Burke, PhD, Co-founder, President and CEO of Applied BioMath.